Paul Tudor Jones’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-650,000
| Closed | -$26.1M | – | 3515 |
|
|
2026
Q1 | $26.1M | Buy |
650,000
+435,000
| +202% | +$9.37M | 0.05% | 320 |
|
|
2025
Q4 | $5.4M | Buy |
+215,000
| New | +$5.04M | 0.01% | 1105 |
|
|
2025
Q2 | – | Sell |
-52,980
| Closed | -$1.16M | – | 3213 |
|
|
2025
Q1 | $1.16M | Buy |
+52,980
| New | +$1.46M | ﹤0.01% | 1720 |
|
|
2024
Q4 | – | Sell |
-73,002
| Closed | -$2.2M | – | 2983 |
|
|
2024
Q3 | $2.11M | Buy |
+73,002
| New | +$2.7M | 0.01% | 1170 |
|
|
2024
Q1 | – | Sell |
-9,962
| Closed | -$596K | – | 2193 |
|
|
2023
Q4 | $596K | Sell |
9,962
-40,150
| -80% | -$2.04M | ﹤0.01% | 1701 |
|
|
2023
Q3 | $1.91M | Buy |
50,112
+42,714
| +577% | +$1.88M | 0.02% | 949 |
|
|
2023
Q2 | $674K | Buy |
+7,398
| New | +$638K | 0.01% | 1543 |
|
|
2022
Q3 | – | Sell |
-34,707
| Closed | -$1.57M | – | 2289 |
|
|
2022
Q2 | $1.57M | Sell |
34,707
-14,133
| -29% | -$644K | 0.04% | 625 |
|
|
2022
Q1 | $2.48M | Buy |
+48,840
| New | +$2.16M | 0.06% | 444 |
|
|
2021
Q4 | – | Sell |
-150,703
| Closed | -$4.97M | – | 2359 |
|
|
2021
Q3 | $4.97M | Buy |
150,703
+128,065
| +566% | +$7.2M | 0.08% | 274 |
|
|
2021
Q2 | $1.43M | Buy |
+22,638
| New | +$1.17M | 0.03% | 703 |
|
|
2021
Q1 | – | Sell |
-29,448
| Closed | -$1.68M | – | 1539 |
|
|
2020
Q4 | $1.68M | Buy |
29,448
+9,507
| +48% | +$402K | 0.05% | 484 |
|
|
2020
Q3 | $602K | Buy |
+19,941
| New | +$596K | 0.03% | 743 |
|
Other funds holding APLS
Paul Tudor Jones's APLS Position: Q2 2026 in Review
Paul Tudor Jones sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 650,000 shares — an estimated $26.1M sold.
Paul Tudor Jones first reported a position in APLS in Q3 2020 and held it in 13 quarters. The position peaked at $26.1M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Paul Tudor Jones reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Paul Tudor Jones sold 650,000 Apellis Pharmaceuticals shares in Q2 2026, an estimated $26.1M.
- Paul Tudor Jones first reported a position in Apellis Pharmaceuticals in Q3 2020 and held it in 13 quarters.
- Paul Tudor Jones's Apellis Pharmaceuticals position peaked at $26.1M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.